camrelizumab,lenalidomide
jiangsu hengrui pharmaceuticals
[' cam ', 'lenalidomide', 'mmsm', ' lena']
mrd2stop trial : stop maintenance if mrd-neg at 10-6 and neg pet. 38 pts enrolled. 5 pts with mrd resurgence, 2 frankly progressed, no deaths at 15 mos f/u. sustained mrd-neg 10-6 at 12 months = 84%. can't wait for qol data! #ash22 #mmsm 
#lymsm & #mmsm hematologist & patient-reported outcomes researcher @CUHematology. Founder of https://t.co/kN6qeGXfg5, @inTrainingDoc & @inHouseMag. ??????